SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (10067)1/20/2004 4:34:20 PM
From: zeta1961  Read Replies (3) | Respond to of 52153
 
If xcytrin works...it will sell itself

Really...the radio-oncology and in this case neuro-radioncology
world is quite small...they all conference and socialize together...I'm not an expert on business development but just know the cancer market...

I don't own PCYC but think it's prospects are excellent....they are even delving into pediatric brain tumors...a validation that the medical community is "bullish" on this....my opinion only...



To: Biomaven who wrote (10067)1/20/2004 8:48:14 PM
From: arnie h  Respond to of 52153
 
Building an independent sales effort, even a small one, isn't a slam dunk when there is uncertainty about whether and when FDA approval will be gotten. It's costly and takes time; especially if you are trying to build a quality sales force. Burn rate can be significantly impacted by developing a sales force that 'sits around' for a while. It would be well to have a feel for what they're thinking about on this.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News